A review of 65 years of human adenovirus seroprevalence

Franck J.D. Mennechet, Océane Paris, Aline Raissa Ouoba, Sofia Salazar Arenas, Sodiomon B. Sirima, Guy R. Takoudjou Dzomo, Amidou Diarra, Isidore T. Traore, Dramane Kania, Karsten Eichholz, Eric A. Weaver, Edouard Tuaillon, Eric J. Kremer

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Introduction: Human adenovirus (HAdV)-derived vectors have been used in numerous pre-clinical and clinical trials during the last 40 years. Current research in HAdV-based vaccines focuses on improving transgene immunogenicity and safety. Because pre-existing humoral immunity against HAdV types correlate with reduced vaccine efficacy and safety, many groups are exploring the development of HAdV types vectors with lower seroprevalence. However, global seroepidemiological data are incomplete. Areas covered: The goal of this review is to centralize 65 years of research on (primarily) HAdV epidemiology. After briefly addressing adenovirus biology, we chronical HAdV seroprevalence studies and highlight major milestones. Finally, we analyze data from about 50 studies with respect to HAdVs types that are currently used in the clinic, or are in the developmental pipeline. Expert opinion: Vaccination is among the most efficient tools to prevent infectious disease. HAdV-based vaccines have undeniable potential, but optimization is needed and antivector immunity remains a challenge if the same vectors are to be administrated to different populations. Here, we identify gaps in our knowledge and the need for updated worldwide epidemiological data.

Original languageEnglish (US)
Pages (from-to)597-613
Number of pages17
JournalExpert Review of Vaccines
Volume18
Issue number6
DOIs
StatePublished - Jun 3 2019

Fingerprint

Human Adenoviruses
Seroepidemiologic Studies
Adenovirus Vaccines
Safety
Expert Testimony
Humoral Immunity
Transgenes
Research
Adenoviridae
Communicable Diseases
Immunity
Vaccination
Epidemiology
Vaccines
Clinical Trials
Population

Keywords

  • Adenovirus
  • gene therapy
  • immunology
  • seroepidemiology
  • vaccination

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Mennechet, F. J. D., Paris, O., Ouoba, A. R., Salazar Arenas, S., Sirima, S. B., Takoudjou Dzomo, G. R., ... Kremer, E. J. (2019). A review of 65 years of human adenovirus seroprevalence. Expert Review of Vaccines, 18(6), 597-613. https://doi.org/10.1080/14760584.2019.1588113

A review of 65 years of human adenovirus seroprevalence. / Mennechet, Franck J.D.; Paris, Océane; Ouoba, Aline Raissa; Salazar Arenas, Sofia; Sirima, Sodiomon B.; Takoudjou Dzomo, Guy R.; Diarra, Amidou; Traore, Isidore T.; Kania, Dramane; Eichholz, Karsten; Weaver, Eric A.; Tuaillon, Edouard; Kremer, Eric J.

In: Expert Review of Vaccines, Vol. 18, No. 6, 03.06.2019, p. 597-613.

Research output: Contribution to journalReview article

Mennechet, FJD, Paris, O, Ouoba, AR, Salazar Arenas, S, Sirima, SB, Takoudjou Dzomo, GR, Diarra, A, Traore, IT, Kania, D, Eichholz, K, Weaver, EA, Tuaillon, E & Kremer, EJ 2019, 'A review of 65 years of human adenovirus seroprevalence', Expert Review of Vaccines, vol. 18, no. 6, pp. 597-613. https://doi.org/10.1080/14760584.2019.1588113
Mennechet FJD, Paris O, Ouoba AR, Salazar Arenas S, Sirima SB, Takoudjou Dzomo GR et al. A review of 65 years of human adenovirus seroprevalence. Expert Review of Vaccines. 2019 Jun 3;18(6):597-613. https://doi.org/10.1080/14760584.2019.1588113
Mennechet, Franck J.D. ; Paris, Océane ; Ouoba, Aline Raissa ; Salazar Arenas, Sofia ; Sirima, Sodiomon B. ; Takoudjou Dzomo, Guy R. ; Diarra, Amidou ; Traore, Isidore T. ; Kania, Dramane ; Eichholz, Karsten ; Weaver, Eric A. ; Tuaillon, Edouard ; Kremer, Eric J. / A review of 65 years of human adenovirus seroprevalence. In: Expert Review of Vaccines. 2019 ; Vol. 18, No. 6. pp. 597-613.
@article{99730e5f901b429584f93e83d3dd85a3,
title = "A review of 65 years of human adenovirus seroprevalence",
abstract = "Introduction: Human adenovirus (HAdV)-derived vectors have been used in numerous pre-clinical and clinical trials during the last 40 years. Current research in HAdV-based vaccines focuses on improving transgene immunogenicity and safety. Because pre-existing humoral immunity against HAdV types correlate with reduced vaccine efficacy and safety, many groups are exploring the development of HAdV types vectors with lower seroprevalence. However, global seroepidemiological data are incomplete. Areas covered: The goal of this review is to centralize 65 years of research on (primarily) HAdV epidemiology. After briefly addressing adenovirus biology, we chronical HAdV seroprevalence studies and highlight major milestones. Finally, we analyze data from about 50 studies with respect to HAdVs types that are currently used in the clinic, or are in the developmental pipeline. Expert opinion: Vaccination is among the most efficient tools to prevent infectious disease. HAdV-based vaccines have undeniable potential, but optimization is needed and antivector immunity remains a challenge if the same vectors are to be administrated to different populations. Here, we identify gaps in our knowledge and the need for updated worldwide epidemiological data.",
keywords = "Adenovirus, gene therapy, immunology, seroepidemiology, vaccination",
author = "Mennechet, {Franck J.D.} and Oc{\'e}ane Paris and Ouoba, {Aline Raissa} and {Salazar Arenas}, Sofia and Sirima, {Sodiomon B.} and {Takoudjou Dzomo}, {Guy R.} and Amidou Diarra and Traore, {Isidore T.} and Dramane Kania and Karsten Eichholz and Weaver, {Eric A.} and Edouard Tuaillon and Kremer, {Eric J.}",
year = "2019",
month = "6",
day = "3",
doi = "10.1080/14760584.2019.1588113",
language = "English (US)",
volume = "18",
pages = "597--613",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - A review of 65 years of human adenovirus seroprevalence

AU - Mennechet, Franck J.D.

AU - Paris, Océane

AU - Ouoba, Aline Raissa

AU - Salazar Arenas, Sofia

AU - Sirima, Sodiomon B.

AU - Takoudjou Dzomo, Guy R.

AU - Diarra, Amidou

AU - Traore, Isidore T.

AU - Kania, Dramane

AU - Eichholz, Karsten

AU - Weaver, Eric A.

AU - Tuaillon, Edouard

AU - Kremer, Eric J.

PY - 2019/6/3

Y1 - 2019/6/3

N2 - Introduction: Human adenovirus (HAdV)-derived vectors have been used in numerous pre-clinical and clinical trials during the last 40 years. Current research in HAdV-based vaccines focuses on improving transgene immunogenicity and safety. Because pre-existing humoral immunity against HAdV types correlate with reduced vaccine efficacy and safety, many groups are exploring the development of HAdV types vectors with lower seroprevalence. However, global seroepidemiological data are incomplete. Areas covered: The goal of this review is to centralize 65 years of research on (primarily) HAdV epidemiology. After briefly addressing adenovirus biology, we chronical HAdV seroprevalence studies and highlight major milestones. Finally, we analyze data from about 50 studies with respect to HAdVs types that are currently used in the clinic, or are in the developmental pipeline. Expert opinion: Vaccination is among the most efficient tools to prevent infectious disease. HAdV-based vaccines have undeniable potential, but optimization is needed and antivector immunity remains a challenge if the same vectors are to be administrated to different populations. Here, we identify gaps in our knowledge and the need for updated worldwide epidemiological data.

AB - Introduction: Human adenovirus (HAdV)-derived vectors have been used in numerous pre-clinical and clinical trials during the last 40 years. Current research in HAdV-based vaccines focuses on improving transgene immunogenicity and safety. Because pre-existing humoral immunity against HAdV types correlate with reduced vaccine efficacy and safety, many groups are exploring the development of HAdV types vectors with lower seroprevalence. However, global seroepidemiological data are incomplete. Areas covered: The goal of this review is to centralize 65 years of research on (primarily) HAdV epidemiology. After briefly addressing adenovirus biology, we chronical HAdV seroprevalence studies and highlight major milestones. Finally, we analyze data from about 50 studies with respect to HAdVs types that are currently used in the clinic, or are in the developmental pipeline. Expert opinion: Vaccination is among the most efficient tools to prevent infectious disease. HAdV-based vaccines have undeniable potential, but optimization is needed and antivector immunity remains a challenge if the same vectors are to be administrated to different populations. Here, we identify gaps in our knowledge and the need for updated worldwide epidemiological data.

KW - Adenovirus

KW - gene therapy

KW - immunology

KW - seroepidemiology

KW - vaccination

UR - http://www.scopus.com/inward/record.url?scp=85068035349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068035349&partnerID=8YFLogxK

U2 - 10.1080/14760584.2019.1588113

DO - 10.1080/14760584.2019.1588113

M3 - Review article

C2 - 31132024

AN - SCOPUS:85068035349

VL - 18

SP - 597

EP - 613

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 6

ER -